Glycolytic inhibitor 2-Deoxy-D-glucose protects against diabetes development in type 1 diabetes models

Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by T cell-mediated pancreatic β-cell destruction. To evaluate the effects of 2-Deoxy-D-Glucose (2DG), a glycolytic inhibitor, on immune cells in autoimmune diabetes, 2DG was orally administered to two T1D mouse models. In a cyclophosphamide-induced T1D model in male non-obese diabetic (NOD) mice, oral 2DG treatment significantly suppressed autoimmune insulitis and diabetes. 2DG treatment showed a significant decrease in the frequencies of CD44 hi CD4 + T cells and CD11b + macrophages, and PD-1 expression level on B cells. Conversely, 2DG-treated mice showed a significant increase in the frequencies of Foxp3 + CD4 + regulatory T cells (Tregs) and PD-L1 + CD11b + macrophages. In addition, Integrin β7 expression level on CD8 + T cells was significantly reduced in 2DG-treated mice. Next, in female NOD mice, a spontaneous T1D model, oral 2DG treatment significantly suppressed autoimmune diabetes progression with a reduction of insulitis. The frequencies of CD11b + macrophages and CD11c + dendritic cells were significantly reduced in 2DG-treated mice. Notably, 2DG treatment significantly increased the frequency of Foxp3 + CD4 + Tregs in both splenocytes and PLN cells. These results suggest that 2DG may suppress autoimmunity and have therapeutic potential in T1D progression by affecting immune cells. In addition, reduced glucose uptake was demonstrated only in B cells, suggesting that metabolic regulation in B cells may contribute to the protective effects of 2DG.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-12
DOI
https://doi.org/10.1038/s41598-026-70088-2
Primary Topic
Diabetes and associated disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glycolytic inhibitor 2-Deoxy-D-glucose protects against diabetes development in type 1 diabetes models

Hisafumi Yasuda, Marina Hayashi, Miku Nishikawa, Aoi Kitada et al.
Scientific Reports
Diabetes and associated disorders
article

Glycolytic inhibitor 2-Deoxy-D-glucose protects against diabetes development in type 1 diabetes models

Hisafumi Yasuda, Marina Hayashi, Miku Nishikawa, Aoi Kitada, Chihiro Minamide, Nanako Maruyama
article en

Abstract

Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by T cell-mediated pancreatic β-cell destruction. To evaluate the effects of 2-Deoxy-D-Glucose (2DG), a glycolytic inhibitor, on immune cells in autoimmune diabetes, 2DG was orally administered to two T1D mouse models. In a cyclophosphamide-induced T1D model in male non-obese diabetic (NOD) mice, oral 2DG treatment significantly suppressed autoimmune insulitis and diabetes. 2DG treatment showed a significant decrease in the frequencies of CD44 hi CD4 + T cells and CD11b + macrophages, and PD-1 expression level on B cells. Conversely, 2DG-treated mice showed a significant increase in the frequencies of Foxp3 + CD4 + regulatory T cells (Tregs) and PD-L1 + CD11b + macrophages. In addition, Integrin β7 expression level on CD8 + T cells was significantly reduced in 2DG-treated mice. Next, in female NOD mice, a spontaneous T1D model, oral 2DG treatment significantly suppressed autoimmune diabetes progression with a reduction of insulitis. The frequencies of CD11b + macrophages and CD11c + dendritic cells were significantly reduced in 2DG-treated mice. Notably, 2DG treatment significantly increased the frequency of Foxp3 + CD4 + Tregs in both splenocytes and PLN cells. These results suggest that 2DG may suppress autoimmunity and have therapeutic potential in T1D progression by affecting immune cells. In addition, reduced glucose uptake was demonstrated only in B cells, suggesting that metabolic regulation in B cells may contribute to the protective effects of 2DG.

Scientific Reports
Kobe University (JP)
Good health and well-being
Diabetes and associated disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon